These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 34543060)
1. Sotorasib: Is Maximum Tolerated Dose Really the Issue at Hand? Soulières D; Gelmon KA J Clin Oncol; 2021 Nov; 39(31):3427-3429. PubMed ID: 34543060 [No Abstract] [Full Text] [Related]
2. Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message? Ratain MJ; Tannock IF; Lichter AS J Clin Oncol; 2021 Nov; 39(31):3423-3426. PubMed ID: 34543056 [No Abstract] [Full Text] [Related]
3. Sotorasib: First Approval. Blair HA Drugs; 2021 Sep; 81(13):1573-1579. PubMed ID: 34357500 [TBL] [Abstract][Full Text] [Related]
4. Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal. Chour A; Basse C; Lebossé F; Bonte PE; Girard N; Duruisseaux M Lung Cancer; 2024 May; 191():107789. PubMed ID: 38614068 [TBL] [Abstract][Full Text] [Related]
5. HER2 mediates clinical resistance to the KRAS Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459 [TBL] [Abstract][Full Text] [Related]
6. FDA Approves Pralsetinib for Treatment of Adults With Metastatic RET Fusion-Positive NSCLC. Wright KM Oncology (Williston Park); 2020 Oct; 34(10):406-406;431. PubMed ID: 33058106 [TBL] [Abstract][Full Text] [Related]
11. Brain Mural Cells Express CAR T-cell Target. Cancer Discov; 2020 Dec; 10(12):1781-1782. PubMed ID: 33097477 [TBL] [Abstract][Full Text] [Related]
12. Advances in the battle against lung tumour resistance. Furlow B Lancet Respir Med; 2014 May; 2(5):353. PubMed ID: 24963524 [No Abstract] [Full Text] [Related]
13. What's Next for Sotorasib in NSCLC? Cancer Discov; 2023 May; 13(5):1033-1034. PubMed ID: 36929750 [TBL] [Abstract][Full Text] [Related]
14. Optimizing Patient Outcomes with PD-1/PD-L1 Immune Checkpoint Inhibitors for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer. La-Beck NM; Nguyen DT; Le AD; Alzghari SK; Trinh ST Pharmacotherapy; 2020 Mar; 40(3):239-255. PubMed ID: 31930528 [TBL] [Abstract][Full Text] [Related]
15. Sotorasib. Am J Health Syst Pharm; 2021 Sep; 78(18):1656-1657. PubMed ID: 34219153 [No Abstract] [Full Text] [Related]
16. After decades, progress against an 'undruggable' cancer target. Kaiser J Science; 2019 Nov; 366(6465):561. PubMed ID: 31672875 [No Abstract] [Full Text] [Related]
17. [Modalities of use of ceritinib (Zykadia™), a 2nd generation ALK inhibitor, in advanced stage non-small cell lung cancer]. Giroux Leprieur E; Fallet V; Wislez M Bull Cancer; 2015 Dec; 102(12):1053-7. PubMed ID: 26597476 [TBL] [Abstract][Full Text] [Related]
18. Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study. Bendaly E; Dalal AA; Culver K; Galebach P; Bocharova I; Foster R; Sasane M; Macalalad AR; Guérin A Adv Ther; 2017 May; 34(5):1145-1156. PubMed ID: 28405961 [TBL] [Abstract][Full Text] [Related]
19. RET fusions in non-small-cell lung cancer: an emerging target reshaping the treatment paradigm. Saleh K; Khalife N; Felefly T Future Oncol; 2021 Apr; 17(12):1445-1448. PubMed ID: 33573417 [No Abstract] [Full Text] [Related]
20. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments. Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]